Sign inSubmit
Tips: “quotes” for a phrase · author:Lee · a DOI goes straight to its article

3 articles for “Tregs”

Set a search alert
Research ArticleOpen accessIn the keywordsAssociation Between Circulating Early Endothelial Progenitors and CD4+CD25+ Regulatory T Cells: A Possible Cross-talk between Immunity and Angiogenesis?Shmuel Schwartzenberg, Adi Mor, Galia Luboshits et al.Regulatory T-cells (Treg) are a recently defined subset of CD4+ cells that can suppress inflammation and induce tolerance. Phenotypically, T-regs are characterized by a high level of expression of the IL-2 receptor alpha chain, CD25. Endothelial progenitor cells (EPCs) can transform into mature endothelial cells and promote vessel formation by inducing postnatal angiogenesis and vasculogenesis. Herein, we tested the hypothesis … …American Journal of Immunology, Vol. 1, Issue 4 · 31 Dec 2005 · 6,902 accessesView PDFCite
Review ArticleOpen accessIn the abstractRole of Cytokines and Transcription Factors in Periodontitis: A Review of Cellular and Molecular MechanismsAnne Carolina Eleutério Leite, Valéria Martins de Araújo Carneiro, Júlia Faria Nunes et al.Periodontal Diseases (PD) are characterized by pathological manifestation of host immune response to bacterial infection at the tooth/gingival interface. Evidences points periodontitis as a risk factor for pathological systemic conditions, such as, cardiovascular diseases and diabetes. The identification of host factors that determine their susceptibility to immune subversion can provide useful information in the pathogenesis of periodontitis. Protective acute inflammatory … …American Journal of Immunology, Vol. 11, Issue 4 · 9 Dec 2015 · 7,807 accessesView PDFCite
EditorialOpen accessIn the abstractAre we Able to Harness the Immunomodulatory Power of Cytokines for Novel Autoimmune Disease Treatments?Giuseppe Nocentini, Graziella Migliorati, Carlo RiccardiSince the end of the 1970s, interleukin 2 (IL-2) has been known as a key player in T cell expansion/activation (Watson et al., 1980). In the late 1980s, some groups used IL-2 to stimulate the immune systems of tumour patients (Jacobs et al., 1986). The idea seemed brilliant and several attempts were made, but the results were disappointing (Lim et … …American Journal of Pharmacology and Toxicology, Vol. 10, Issue 2 · 22 Oct 2015 · 7,625 accessesView PDFCite